|Dr. Eric E. Poma||CEO, Chief Scientific Officer & Director||820.9k||N/A||1972|
|Ms. Jason S Kim||Pres & COO||590.25k||N/A||1975|
|Dr. Roger J. Waltzman||Chief Medical Officer||572.91k||N/A||1968|
|Mr. Sean McLennan||Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer||N/A||N/A||1970|
|Mr. Kurt Elster||Exec. VP of Corp. Devel.||N/A||N/A||1967|
|Dr. Jack Higgins Ph.D.||Exec. VP of Operations & Head of Manufacturing||N/A||N/A||1980|
|Dr. Erin Willert Ph.D.||Exec. VP of R&D||N/A||N/A||1982|
|Dr. Jen-Sing Liu Ph.D.||Exec. VP of Manufacturing||N/A||N/A||1963|
|Dr. Nenad Sarapa M.D., M.S.||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.
Molecular Templates, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 6; Compensation: 8.